Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma – An analysis of the EORTC 62012 study of the EORTC STBSG

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

World Health Organization, Solid Tumors, Cancer Management +17

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

Ian Judson, Jaap Verweij, Hans Gelderblom et al. · The Lancet Oncology · 2014 · 1.1K citations · Full text

Metastatic Soft-tissue Sarcoma, Versus Intensified Doxorubicin, Oncology +7

Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study

M. van Glabbeke, A.T. van Oosterom, J. Wolter Oosterhuis et al. · Journal of Clinical Oncology · 1999 · 565 citations

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Armando Santoro, T Türsz, Henning T. Mouridsen et al. · Journal of Clinical Oncology · 1995 · 526 citations

Challenges of Guarantee-Time Bias

Anita Giobbie‐Hurder, Richard D. Gelber, Meredith M. Regan · Journal of Clinical Oncology · 2013 · 430 citations · Full text

Engineering, Prognosis, Verification +21